Litigation Details for Actelion Pharmaceuticals US, Inc. v. Lupin Ltd. (D. Del. 2023)

Actelion Pharmaceuticals US, Inc. v. Lupin Ltd. (D. Del. 2023)

Docket		Date Filed	2023-02-09
Court	District Court, D. Delaware	Date Terminated	2024-02-14
Cause	35:1 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Patents	8,791,122; 9,284,280
Link to Docket	External link to docket

Details for Actelion Pharmaceuticals US, Inc. v. Lupin Ltd. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-02-09				External link to document

Litigation summary and analysis for: Actelion Pharmaceuticals US, Inc. v. Lupin Ltd. (D. Del. 2023)

Last updated: July 22, 2026

Actelion v. Lupin (1:23-cv-00150) litigation summary and patent-attack analysis

Executive summary: Actelion Pharmaceuticals US, Inc. v. Lupin Ltd. (U.S. District Court, 1:23-cv-00150) is a patent infringement case filed in 2023 by Actelion targeting Lupin’s proposed generic competition for a protected Actelion product. The litigation posture is consistent with an ANDA Hatch-Waxman dispute, with Actelion seeking injunctive relief and damages tied to Orange Book-listed patents and/or method-of-use, formulation, and/or manufacturing method claims. The risk for Lupin turns on claim coverage breadth versus anticipated design-around routes, and on whether any asserted claims survive dispositive motions on validity, infringement, and written description/enablement.

What follows: Litigation-only summary and business analysis keyed to the docket identifier 1:23-cv-00150.

---

What is Actelion Pharmaceuticals US v. Lupin Ltd. 1:23-cv-00150 about?

Case type. A U.S. patent infringement suit brought by Actelion Pharmaceuticals US, Inc. against Lupin Ltd. under the Hatch-Waxman framework (typical for Paragraph IV cases and Orange Book patent disputes).

Core dispute. Actelion alleges Lupin’s commercial or proposed generic manufacture, use, sale, offer for sale, or importation would infringe Actelion’s U.S. patents covering the reference drug’s active ingredient(s), dosage forms, formulations, and/or labeled uses, as reflected in FDA’s Orange Book patent listings for the reference product.

Relief sought (typical). Injunction to block commercial entry before patent expiration, plus damages for infringement during the relevant pre-entry window if entry occurred or was authorized.

---

When was 1:23-cv-00150 filed, and what litigation milestones matter for exclusivity leverage?

Filing year and posture. Filed in 2023. In this posture, the key milestones that determine commercial timing usually include:

• Court scheduling of claim construction (Markman) and expert deadlines
• Rule 12/summary judgment events that narrow asserted claims
• Any stipulations or partial dismissals of asserted patents
• Settlement terms if the parties agree to non-entry until a defined “carve-out” date

Decision timeline effect. Hatch-Waxman patent disputes often reach a litigation “fork” around claim construction and dispositive motion rounds. Early narrowing of asserted claims increases settlement probability. If Lupin retains invalidity and non-infringement defenses for core claims, settlement leverage shifts toward Actelion only if infringement is straightforward on the accused product.

---

Which patents does Actelion assert in 1:23-cv-00150, and how does that shape the infringement theory?

Patent estate dependency. In cases of this type, the asserted patents usually fall into one or more of these buckets:

1) Drug substance and composition-of-matter

• Broadest coverage for active ingredient and related chemical entities
• Highest stakes for Lupin’s “all-at-once” non-infringement argument

2) Formulation patents

• Coverage for specific dosage forms, excipients, coatings, release systems
• Strong for generics where formulation-level changes are technically or regulatorily constrained

3) Method-of-use or treatment regimen patents

• Coverage for dosing and specific indications
• Strong where the generic seeks FDA approval with the same labeled instructions

4) Manufacturing method or process patents

• Coverage for steps in producing a drug
• Requires proof of process infringement, which can be harder for plaintiffs without discovery of manufacturing details

Business impact: If Actelion’s asserted claims skew toward formulation or method-of-use rather than pure composition-of-matter, Lupin’s best route often becomes design-around plus labeling carve-outs. If composition-of-matter claims are asserted and remain valid, Lupin’s options narrow to licensing or delayed launch.

---

What is the Orange Book status of the Actelion product at issue in 1:23-cv-00150?

Orange Book linkage. In Hatch-Waxman litigation, asserted patents typically correspond to patents listed for the reference drug in FDA’s Orange Book at the time of the ANDA filing and the Paragraph IV notice.

How Orange Book status drives leverage:

• If multiple Orange Book patents are asserted, Actelion can pressure settlement by offering entry only after the earliest-to-expire “blocking” patent.
• If Lupin successfully knocks out one or more asserted patents early, the remaining patent set determines the actual “effective” exclusivity.

Litigation mapping approach (used in Hatch-Waxman cases):

• Identify each asserted Orange Book patent
• Track its expiration and any pediatric exclusivity
• Evaluate expected invalidity grounds: §101, §102/§103, §112 enablement/written description
• Tie each patent to likely infringement evidence: product composition, label, manufacturing documentation

---

How strong is Actelion’s patent estate in this dispute?

Strength factors that typically decide outcomes:

Claim breadth

• Composition claims tend to be harder for generics to avoid.
• Formulation and method-of-use claims are vulnerable if the generic uses a different formulation route or a non-infringing label.

Prior art and obviousness posture

• Strong estates are those with clean prosecution histories and narrow obviousness vulnerabilities.
• Weak estates show overlap between asserted claim scope and widely known prior art dosage/formulation approaches.

Written description and enablement

• Formulation claims are vulnerable if the specification does not clearly support the claimed parameter space (e.g., excipient ratios, particle size ranges, release kinetics).
• Method-of-use claims can fail if labeling-adjacent dosing regimens are not well supported.

Commercial and technical fit

• If Actelion’s infringement theory relies on straightforward, measurable aspects of the Lupin product (e.g., dissolution profile or excipient selection), infringement motions become easier.
• If Actelion must prove a manufacturing process step, litigation often becomes discovery-heavy and slower.

Business conclusion: The litigation’s value depends on which patent classes Actelion asserted. Composition-of-matter dominance signals high settlement probability at a higher price point. Formulation/method-of-use dominance signals a higher probability of a partial carve-out settlement, with entry permitted after one or more patents are cleared.

---

What infringement arguments does Actelion typically use against a Lupin generic in an ANDA case like this?

Actelion’s infringement theory in ANDA litigation generally tracks one-to-one with the accused product and the ANDA’s proposed FDA labeling:

• Literal infringement: direct claim mapping to the generic’s formulation, dosage form, or labeled method-of-use.
• Infringement by equivalence: used when the generic changes a parameter but retains core claim limitations.
• Label-based infringement: for method-of-use claims, the label controls infringement scope in the ANDA context.

Key technical proof areas:

• Dissolution and release testing for formulation patents
• Claim parameter compliance (particle size, excipient identity, coating composition, etc.)
• Labeling correspondence to claimed regimen and patient population

---

What defenses does Lupin typically raise, and how do they affect launch timing?

Common Lupin (generic) defenses in such cases include:

• Non-infringement: accused product does not meet all claim limitations
• Invalidity: anticipation/obviousness (prior art), indefiniteness, and §112 vulnerabilities
• Statutory bars: if procedural timing or jurisdictional issues arise
• No causation of damages: if launch did not occur or if entry is enjoined

Launch timing impact:

• If Lupin wins on non-infringement for the “blocking” claim, Actelion must pivot to remaining patents.
• If Lupin wins invalidity on a core patent, entry becomes more feasible without licensing.

---

Does 1:23-cv-00150 involve a Paragraph IV ANDA, and what does that mean for generic entry risk?

Typical Hatch-Waxman meaning: A case identified as Actelion vs. Lupin over a protected product is usually tied to an ANDA containing a Paragraph IV certification. In that scenario:

• The filing triggers an automatic 30-month stay if FDA approval is sought before final resolution.
• The outcome determines whether FDA approval converts into launch authorization.
• Settlement agreements often include “no-launch” covenants until a defined date tied to patent expiration.

Generic entry risk assessment framework:

• Determine whether the asserted patents are still in force and which ones control effective exclusivity.
• Evaluate whether Lupin’s product is likely to face immediate appeal or further stay effects after district court rulings.

---

What patent litigation outcomes are most likely to trigger settlement in Hatch-Waxman cases like this?

Settlement triggers that routinely show up in similar disputes:

• Claim construction narrows claim scope against the plaintiff’s theory
• Dispositive motion eliminates several asserted patents
• Summary judgment converts the remaining “core” patents into a high-confidence infringement finding
• Parties agree on a predictable entry date with royalty or payment structure

Business pattern: When multiple patents are asserted, settlements often carve out a subset of “surviving” patents. Entry is then permitted only after the last blocking patent expires or is found invalid/non-infringing.

---

How do biosimilar risk and biologics rules apply here?

Relevance: Actelion Pharmaceuticals US, Inc. v. Lupin Ltd. in 1:23-cv-00150 is a patent infringement case between a branded company and a generic entrant, structured like an ANDA dispute. The biosimilar pathway frameworks (BLA, 351(k)) typically apply to biologics, not ANDAs.

Practical point for strategy: The litigation and risk model is small-molecule generic exclusivity style: Orange Book patents and Paragraph IV certifications, not biosimilar interchangeability.

---

What is the most likely commercial exposure for Actelion and Lupin tied to this case?

Actelion exposure:

• Loss of exclusivity if Lupin clears the blocking patents and launches
• Potential price erosion across the protected product’s revenue base
• Need for defensive litigation across a multi-patent estate

Lupin exposure:

• Cost of litigating and potential damages if FDA approval and launch occur during an infringement period
• Opportunity cost tied to the 30-month stay window and any settlement no-launch period
• License risk if Actelion retains leverage on core claims

---

Key takeaways

• 1:23-cv-00150 is a Hatch-Waxman-style patent infringement dispute filed in 2023 by Actelion Pharmaceuticals US, Inc. against Lupin Ltd. over an Actelion protected product.
• The commercial impact hinges on which Orange Book-listed patents Actelion asserted and whether those patents are composition/formulation/method-of-use claims that are hardest to design around.
• Lupin’s outcomes usually depend on claim construction and whether Actelion’s infringement evidence is primarily product composition/label-based (fast for plaintiffs) or process-based (often slower due to discovery needs).
• Settlement likelihood increases if dispositive rulings narrow the case to one or a few “blocking” patents with predictable expiration timing.

---

FAQs

1) What court and case designation governs Actelion v. Lupin at 1:23-cv-00150?

U.S. District Court, case number 1:23-cv-00150, captioned Actelion Pharmaceuticals US, Inc. v. Lupin Ltd.

2) Does Actelion v. Lupin 1:23-cv-00150 require proof of the Lupin manufacturing process?

That depends on whether the asserted claims are manufacturing-method claims versus composition/formulation or label-based method-of-use claims. In ANDA disputes, non-process claims often rely on product characteristics and labeling.

3) How do claim construction rulings typically change settlement leverage in Actelion-style Hatch-Waxman cases?

They narrow claim scope, which can either strengthen infringement mapping for Actelion or create non-infringement/design-around paths for Lupin.

4) What happens to FDA approval timing if the litigation stays in place?

The case typically sits alongside the Hatch-Waxman stay mechanics tied to ANDA Paragraph IV certification, delaying market entry until resolution or a settlement trigger date.

5) What patent category usually determines the effective launch date for generics in these disputes?

The last remaining “blocking” patent category among the asserted set, usually an Orange Book-listed composition, formulation, or method-of-use patent with the latest effective expiration.

---

References (APA)

1. U.S. District Court. Actelion Pharmaceuticals US, Inc. v. Lupin Ltd., No. 1:23-cv-00150 (Docket, 2023).